Portal de Periódicos da CAPES

Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention

2024; Volume: 3; Issue: 6 Linguagem: Inglês

10.1056/evidoa2300311

2766-5526

George Du Toit, Michelle F. Huffaker, Suzana Radulovič, Mary Feeney, Helen R. Fisher, M. Byron, Lars Dunaway, Agustin Calatroni, Molly Johnson, Ru‐Xin Foong, Andreina Marques‐Mejias, Irene Bartha, Monica Basting, Helen A. Brough, Carolyn H. Baloh, Tanya M. Laidlaw, Henry T. Bahnson, Graham Roberts, Marshall Plaut, Lisa M. Wheatley, Gideon Lack,

Child Nutrition and Feeding Issues

BackgroundA randomized trial demonstrated consumption of peanut from infancy to age 5 years prevented the development of peanut allergy. An extension of that trial demonstrated the effect persisted after 1 year of peanut avoidance. This follow-up trial examined the durability of peanut tolerance at age 144 months after years of ad libitum peanut consumption.MethodsParticipants from a randomized peanut consumption trial were assessed for peanut allergy following an extended period of eating or avoiding peanuts as desired. The primary end point was the rate of peanut allergy at age 144 months.ResultsWe enrolled 508 of the original 640 participants (79.4%); 497 had complete primary end point data. At age 144 months, peanut allergy remained significantly more prevalent in participants in the original peanut avoidance group than in the original peanut consumption group (15.4% [38 of 246 participants] vs. 4.4% [11 of 251 participants]; P<0.001). Participants in both groups reported avoiding peanuts for prolonged periods of time between 72 and 144 months. Participants at 144 months in the peanut consumption group had levels of Ara h2-specific immunoglobulin E (a peanut allergen associated with anaphylaxis) of 0.03 ± 3.42 kU/l and levels of peanut-specific immunoglobulin G4 of 535.5 ± 4.98 μg/l, whereas participants in the peanut avoidance group had levels of Ara h2-specific immunoglobulin E of 0.06 ± 11.21 kU/l and levels of peanut-specific immunoglobulin G4 of 209.3 ± 3.84 μg/l. Adverse events were uncommon, and the majority were related to the food challenge.ConclusionsPeanut consumption, starting in infancy and continuing to age 5 years, provided lasting tolerance to peanut into adolescence irrespective of subsequent peanut consumption, demonstrating that long-term prevention and tolerance can be achieved in food allergy. (Funded by the National Institute of Allergy and Infectious Diseases and others; ITN070AD, ClinicalTrials.gov number, NCT03546413.)